Pelthos Therapeutics Appoints John M. Gay as CFO Succeeding Francis Knuettel II

On April 10, 2026, Pelthos Therapeutics Inc. appointed John M. Gay as Chief Financial Officer, Treasurer, and Secretary. Mr. Gay, age 49, previously served as the Company’s Senior Vice President of Finance & Accounting since July 2025. His extensive background includes CFO roles at LNHC, Inc. and Novan, Inc., as well as positions at Furiex Pharmaceuticals and Deloitte. In connection with his appointment, Mr. Gay entered into an employment agreement providing for an annual base salary of $425,000 and a target annual bonus of 40% of his base salary. Concurrently, the Board terminated Francis Knuettel II from his position as Chief Financial Officer, effective April 10, 2026. The Company stated that Mr. Knuettel’s departure was not due to any disagreement regarding operations, policies, or practices. Pelthos expects to enter into a separation agreement with Mr. Knuettel in accordance with his existing employment terms. The transition occurs as Pelthos continues the commercialization of its lead product, ZELSUVMI, for the treatment of molluscum contagiosum.